Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial

Dementia Clinical Trial

Official title:

Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05860127
• Other study ID #: Pro00054748
• Secondary ID: 5U54AG063546-04
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 10, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: May 2024
• Source: University of Massachusetts, Amherst
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cognitive Stimulation Therapy (CST) is an evidence-based non-pharmacological group therapy shown to benefit people with mild to moderate dementia. Despite increasing availability of CST worldwide, access remains limited in the United States. This pilot pragmatic trial will embed CST referral into the standard care protocol of health care settings that serve people living with dementia in the state of Connecticut, and evaluate online delivery of CST known as virtual CST (V-CST), and assess the acceptability of V-CST to people living with dementia.

The study design is a two-armed randomized embedded pragmatic clinical trial (ePCT). The trial aims to determine if cognitive decline is experienced less commonly among V-CST participants than control group members based on three widely used measures of cognition, the Montreal Cognitive Assessment (MoCA), St. Louis University Memory Screen (SLUMS), and Mini Mental State Exam (MMSE).

The study population will be persons with mild to moderate dementia identified by clinicians in standard care. From this population, subject participants will be randomized to intervention and control groups. Patients randomly assigned to the intervention group will be referred by their clinical providers to participate in V-CST, and those who accept the referral will participate in the intervention.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 133
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Mild Cognitive Impairment or Mild to Moderate Dementia

• MoCA score of 10 to 26 OR SLUMS score of 10 to 26 OR MMSE score between 13 and 24 recorded as present < 24 months before the record review

• English-speaking

• Visit scheduled to include cognitive screening 6 to 12 months after record review.

Exclusion Criteria:

• Auditory or visual impairment, combative behaviors, or other clinician-assessed condition that would interfere with group treatment

• No access to online meeting platform

• Patient has specified to HCS not to engage patient in research or to use patient data in research

• Patient has previously participated in V-CST

• Physician determines a caregiver is needed to support V-CST participation, but no caregiver available to assist with technology.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Cognitive Impairment, Mild
• Dementia
• Dementia Frontal
• Dementia Moderate
• Dementia of Alzheimer Type
• Dementia With Lewy Bodies
• Dementia, Mild
• Dementia, Mixed
• Dementia, Vascular
• Lewy Body Disease

Intervention

Behavioral:
• Referral for Cognitive Stimulation Therapy
Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement

Other:
• No change to Standard of Care
Participants will not receive referral from a physician. They will continue with standard of care at their site.

Locations

Country	Name	City	State
United States	UConn Center on Aging	Farmington	Connecticut
United States	Yale Memory Clinic	New Haven	Connecticut

Sponsors (5)

Lead Sponsor	Collaborator
University of Massachusetts, Amherst	National Institute on Aging (NIA), UConn Health, University of Maryland, Baltimore, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive decline measured by an increase in Montreal Cognitive Assessment Score from baseline to follow-up	Clinically meaningful cognitive decline will be less common in intervention group than the control group. Clinically meaningful changes will be assessed using one of the following cognitive assessment tools: Montreal Cognitive Assessment (MoCA), Saint Louis University Mental Status (SLUMS) exam, or the Mini-Mental State Examination (MMSE). A 'crosswalk' will be used to convert all cognitive assessment measures to a MoCA score. All participants will start with a baseline MoCA score of 10 to 26 which indicates mild-moderate cognitive impairment. An increase in the baseline MoCA score by 2 points or greater indicates a clinically meaningful decline in cognitive status. Cognitive assessments will be collected at baseline and 6 months follow-up visit after baseline/enrollment. All cognitive assessments will be done by the study physicians. The cognitive assessment collected at baseline will be the cognitive assessment used to assess cognitive impairment at the 6 month follow-up.	6 months
Secondary	Cognitive improvement measured by a decrease in Montreal Cognitive Assessment Score from baseline to follow-up	Clinically meaningful cognitive improvement will be more common in the intervention group than the control group. Clinically meaningful changes will be assessed using one of the following cognitive assessment tools: Montreal Cognitive Assessment (MoCA), Saint Louis University Mental Status (SLUMS) exam, or the Mini-Mental State Examination (MMSE). A 'crosswalk' will be used to convert all cognitive assessment measures to a MoCA score. All participants will start with a baseline MoCA score of 10 to 26 which indicates mild-moderate cognitive impairment. A decrease in the baseline MoCA score by 2 points or greater indicates a clinically meaningful improvement in cognitive status. Cognitive assessments will be collected at baseline and 6 months follow-up visit after baseline/enrollment. All cognitive assessments will be done by the study physicians. The cognitive assessment collected at baseline will be the cognitive assessment used to assess cognitive impairment at the 6 month follow-up.	6 months
Secondary	Referral Acceptance Rate	V-CST referral will be favorably received by participants. V-CST referral will be assessed by referral acceptance rate measured by percentage of people referred for V-CST who accept the referral over the 1-month referral period process. This outcome will be assessed at the end of the referral process.	1 month
Secondary	Participant attendance	V-CST treatment will be favorably received by participants. Participant attendance will be measured as the percentage of enrolled participants who attend each V-CST session. V-CST sessions will be conducted over a 7-week period. This outcome will be assessed at the end of the 7th week V-CST session.	7 weeks
Secondary	Participant Attrition	V-CST treatment will be favorably received by participants. Participant attrition will be measured as the percentage of enrolled participants who cease attending V-CST between session 1 and session 14. V-CST sessions will be conducted over a 7-week period. This outcome will be assessed at the end of the 7th week V-CST session.	7 weeks